ClinicalTrials.gg
CompletedNCT03657043Updated May 6, 2023Results posted

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

A Phase 2 interventional study of tisotumab vedotin in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer, sponsored by Seagen Inc.. Completed at 37 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.

Enrollment
13th of 38
98 · median 52
Started
2019
with 2 others
Phase 2
7 of 38
none open now
Registered
16th of 38
by date

Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 13th largest by enrollment, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 16th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Ovarian Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).

Read the detailed description

The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week cycle (3Q4W) for patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has relapsed within 6 months of the completion of platinum-based treatment and determined to be platinum resistant. All patients must have PROC and be eligible for single agent chemotherapy.

The safety run-in period will evaluate the safety of a weekly schedule. The highest dose level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1, 8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified. Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is considered safe and tolerable in the safety run-in period.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Keywords

  • Platinum-resistant
  • Antibody drug conjugate
  • Tisotumab vedotin
  • PROC
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Safety run-in only: PROC. Patients may have received more than 1 prior systemic treatment regimen in the PROC setting.
  • Part A and Part B only: Patients with PROC who have received 1 to 3 anticancer overall, including at least 1 line of therapy containing bevacizumab or biosimilar.

    • Adjuvant ± are considered 1 line of therapy.
    • Patients may have received a PARP inhibitor or an immuno-oncology (IO) agent; any of these regimens are to be considered a line of therapy for the purposes of this study if not used as maintenance therapy.
    • Maintenance therapy (including bevacizumab, PARP inhibitors and IOs) will be considered part of the preceding line of therapy and not to be counted as a new line of therapy.
    • Any chemotherapy regimen change due to toxicity in the absence of disease progression is considered as part of the same line of therapy.
    • Hormonal therapy will be not be counted towards the lines of therapy.
  • according to v1.1 as assessed by the investigator
  • An (ECOG) Performance Status score of 0 or 1
  • of at least 3 months
  • Able to provide fresh or for biomarker analysis

Exclusion criteria

Exclusion Criteria:

  • Primary platinum- disease, defined as disease progression within 2 months of completion of platinum-based therapy
  • Patients with clinical symptoms or signs of gastrointestinal obstruction with the past 6 months or who currently require parenteral nutrition
  • Hematological: Known past or current coagulation defects leading to an increased risk of bleeding, diffuse alveolar hemorrhage from vasculitis, known bleeding diathesis, ongoing major bleeding, or trauma with increased risk of life-threatening bleeding within 8 weeks of trial entry
  • Cardiovascular: cardiac disease including uncontrolled hypertension, unstable angina, acute myocardial infarction with 6 months of screening, serious cardiac arrhythmia requiring medication, medical history of congestive heart failure, or medical history of decreased cardiac of \<45%
  • Ophthalmological: Active ocular surface disease at baseline or prior episode of cicatricial conjunctivitis or Stevens Johnson syndrome
  • Prior treatment with MMAE-derived drugs
  • Inflammatory bowel disease including Crohn's disease and ulcerative colitis
  • Ongoing, acute, or chronic inflammatory skin disease
  • Uncontrolled tumor-related pain
  • Inflammatory lung disease requiring chronic medical therapy
  • Grade 3 or higher pulmonary disease unrelated to underlying
  • Uncontrolled pleural or pericardial effusions
  • Grade >1 peripheral neuropathy
  • Patients who are pregnant or breastfeeding
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Safety Run-In (3Q4W Schedule)

    28-day, 3 dose cycle

    Drug: tisotumab vedotin

  • Experimental
    Part A: Tisotumab Vedotin

    21-day, single dose cycle

    Drug: tisotumab vedotin

  • Experimental
    Part A: Tisotumab Vedotin (3Q4W Schedule)

    28-day, 3 dose cycle

    Drug: tisotumab vedotin

  • Experimental
    Part B: Tisotumab Vedotin (3Q4W Schedule)

    28-day, 3 dose cycle

    Drug: tisotumab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)

    Incidence of dose-limiting toxicity (DLT) was evaluated in participants enrolled in the Safety Run-In, who were followed for protocol-defined DLT events up to 28 days after the first dose of tisotumab vedotin.

    Time frame: Up to 28 days

  2. Confirmed Objective Response Rate (ORR) (Part B)

    Proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator

    Time frame: Up to 9.7 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) (Part B)

    An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.

    Time frame: Up to 23.0 months

  2. Confirmed and Unconfirmed ORR (Part B)

    Proportion of participants who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator

    Time frame: Up to 9.7 months

  3. Cancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B)

    Percentage of participants who have at least a 50% reduction in CA-125 value from baseline

    Time frame: Up to 10.1 months

  4. Overall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B)

    Percentage of participants whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria

    Time frame: Up to 10.1 months

  5. Duration of Response (DOR) (Part B)

    Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first

    Time frame: Up to 8.3 months

  6. Disease Control Rate (DCR) (Part B)

    Percentage of participants who achieved a confirmed Complete Response(CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator, or meet the Stable Disease (SD) criteria at least once after start of study treatment at a minimum interval of 12 weeks.

    Time frame: Up to 3.0 months

  7. Time to Response (TTR) (Part B)

    Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)

    Time frame: Up to 23.0 months

  8. Progression-free Survival (PFS) (Part B)

    Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first

    Time frame: Up to 9.7 months

  9. Overall Survival (OS) (Part B)

    Time from the start of study treatment to date of death due to any cause

    Time frame: Up to 23.0 months

  10. Incidence of Antitherapeutic Antibodies (ATA) (Part B)

    The proportion of participants who develop ATA at any time during the study. A positive baseline ATA result is considered positive post-baseline if the post-baseline ATA titer result is at least four times higher than the baseline result.

    Time frame: Up to 6.9 months

  11. Pharmacokinetic (PK) Parameter: Antibody-Drug Conjugate (ADC) Maximum Concentration (Cmax) (Part B)

    ADC Cmax was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  12. PK Parameter: ADC Time of Cmax (Tmax) (Part B)

    ADC Tmax was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  13. PK Parameter: ADC Area Under Concentration-Time Curve (AUC) (Part B)

    ADC AUC was derived from the PK blood samples collected.

    Time frame: Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose).

  14. PK Parameter: Free Monomethyl Auristatin E (MMAE) Cmax (Part B)

    MMAE Cmax was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  15. PK Parameter: MMAE Tmax (Part B)

    MMAE Tmax was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  16. PK Parameter: MMAE AUC (Part B)

    MMAE AUC was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  17. PK Parameter: MMAE Trough Concentration (Ctrough) (Part B)

    MMAE Ctrough was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  18. PK Parameter: Total Antibody (TAb) Cmax (Part B)

    TAb Cmax was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  19. PK Parameter: TAb Tmax (Part B)

    TAb Tmax was derived from the PK blood samples collected.

    Time frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.

  20. PK Parameter: TAb Area Under Concentration-Time Curve (AUC) (Part B)

    TAb AUC was derived from the PK blood samples collected.

    Time frame: Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose).

07

Results

Posted May 6, 2023

Participant flow

A total of 98 participants were enrolled into the Safety Run-In and Part B Expansion cohorts, of which 94 received study drug. No participants were enrolled into Part A.

Participant flow — Overall Study
MilestoneSafety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart A Q3WPart A 3Q4WPart B Expansion
Started880082
Completed00000
Not completed880082
Withdrew: Withdrawal by subject11004
Withdrew: Study closure by sponsor020017
Withdrew: Lost to follow-up00004
Withdrew: Death650053
Withdrew: Met exclusion criteria after enrollment10000
Withdrew: Adverse event00002
Withdrew: Withdrawal - subsequent treatment00001
Withdrew: Withdrawal - declined follow-up00001

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)

Incidence of dose-limiting toxicity (DLT) was evaluated in participants enrolled in the Safety Run-In, who were followed for protocol-defined DLT events up to 28 days after the first dose of tisotumab vedotin.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)
ParticipantsSafety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4W
Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)01
PrimaryConfirmed Objective Response Rate (ORR) (Part B)

Proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator

Time frame:
Up to 9.7 months
Reported as:
Count of participants · Participants
Confirmed Objective Response Rate (ORR) (Part B)
ParticipantsPart B Expansion
Confirmed Objective Response Rate (ORR) (Part B)7
SecondaryNumber of Participants With Adverse Events (AEs) (Part B)

An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.

Time frame:
Up to 23.0 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) (Part B)
ParticipantsPart B Expansion
Any TEAE79
Treatment-related TEAE67
Treatment-related Grade 3-4 TEAE14
Treatment-related Grade 5 TEAE0
Max severity of TEAE - Grade 17
Max severity of TEAE - Grade 235
Max severity of TEAE - Grade 332
Max severity of TEAE - Grade 43
Max severity of TEAE - Grade 52
Any treatment-emergent serious AE (SAE)28
Treatment-related SAE6
SecondaryConfirmed and Unconfirmed ORR (Part B)

Proportion of participants who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator

Time frame:
Up to 9.7 months
Reported as:
Number · Percentage of Participants
Confirmed and Unconfirmed ORR (Part B)
Percentage of ParticipantsPart B Expansion
Confirmed and Unconfirmed ORR (Part B)18.0 (10.0 to 27.9)
SecondaryCancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B)

Percentage of participants who have at least a 50% reduction in CA-125 value from baseline

Time frame:
Up to 10.1 months
Reported as:
Number · Percentage of Participants
Cancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B)
Percentage of ParticipantsPart B Expansion
Cancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B)12.0 (4.4 to 23.9)
SecondaryOverall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B)

Percentage of participants whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria

Time frame:
Up to 10.1 months
Reported as:
Number · Percentage of Participants
Overall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B)
Percentage of ParticipantsPart B Expansion
Overall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B)11.0 (5.3 to 20.5)
SecondaryDuration of Response (DOR) (Part B)

Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first

Time frame:
Up to 8.3 months
Reported as:
Median · Months
Duration of Response (DOR) (Part B)
MonthsPart B Expansion
Duration of Response (DOR) (Part B)4.21 (3.02 to NA)
SecondaryDisease Control Rate (DCR) (Part B)

Percentage of participants who achieved a confirmed Complete Response(CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator, or meet the Stable Disease (SD) criteria at least once after start of study treatment at a minimum interval of 12 weeks.

Time frame:
Up to 3.0 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) (Part B)
Percentage of ParticipantsPart B Expansion
Disease Control Rate (DCR) (Part B)54.4 (42.8 to 65.7)
SecondaryTime to Response (TTR) (Part B)

Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)

Time frame:
Up to 23.0 months
Reported as:
Median · Months
Time to Response (TTR) (Part B)
MonthsPart B Expansion
Time to Response (TTR) (Part B)1.4 (1.0 to 3.0)
SecondaryProgression-free Survival (PFS) (Part B)

Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first

Time frame:
Up to 9.7 months
Reported as:
Median · Months
Progression-free Survival (PFS) (Part B)
MonthsPart B Expansion
Progression-free Survival (PFS) (Part B)2.73 (1.64 to 2.99)
SecondaryOverall Survival (OS) (Part B)

Time from the start of study treatment to date of death due to any cause

Time frame:
Up to 23.0 months
Reported as:
Median · Months
Overall Survival (OS) (Part B)
MonthsPart B Expansion
Overall Survival (OS) (Part B)10.68 (7.75 to 12.81)
SecondaryIncidence of Antitherapeutic Antibodies (ATA) (Part B)

The proportion of participants who develop ATA at any time during the study. A positive baseline ATA result is considered positive post-baseline if the post-baseline ATA titer result is at least four times higher than the baseline result.

Time frame:
Up to 6.9 months
Reported as:
Count of participants · Participants
Incidence of Antitherapeutic Antibodies (ATA) (Part B)
ParticipantsPart B Expansion
Baseline Negative - Negative post-baseline65
Baseline Negative - Positive post-baseline3
Baseline Positive - Negative post-baseline3
Baseline Positive - Positive post-baseline0
SecondaryPharmacokinetic (PK) Parameter: Antibody-Drug Conjugate (ADC) Maximum Concentration (Cmax) (Part B)

ADC Cmax was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · µg/mL
Pharmacokinetic (PK) Parameter: Antibody-Drug Conjugate (ADC) Maximum Concentration (Cmax) (Part B)
µg/mLPart B Expansion
Cycle 1, Dose 120.582 ± 26.963
Cycle 1, Dose 321.817 ± 26.823
SecondaryPK Parameter: ADC Time of Cmax (Tmax) (Part B)

ADC Tmax was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · Days
PK Parameter: ADC Time of Cmax (Tmax) (Part B)
DaysPart B Expansion
Cycle 1, Dose 10.041 ± 53.112
Cycle 1, Dose 30.041 ± 78.407
SecondaryPK Parameter: ADC Area Under Concentration-Time Curve (AUC) (Part B)

ADC AUC was derived from the PK blood samples collected.

Time frame:
Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose).
Reported as:
Geometric mean · µg/mL*day
PK Parameter: ADC Area Under Concentration-Time Curve (AUC) (Part B)
µg/mL*dayPart B Expansion
Cycle 1, Dose 1 - AUC 7 Days-ADC25.198 ± 25.335
Cycle 1, Dose 3 - AUC 7 Days-ADC30.159 ± 32.261
Cycle 1, Dose 3 - AUC 14 Days-ADC31.716 ± 31.632
SecondaryPK Parameter: Free Monomethyl Auristatin E (MMAE) Cmax (Part B)

MMAE Cmax was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · ng/mL
PK Parameter: Free Monomethyl Auristatin E (MMAE) Cmax (Part B)
ng/mLPart B Expansion
Cycle 1, Dose 11.778 ± 66.636
Cycle 1, Dose 32.552 ± 52.442
SecondaryPK Parameter: MMAE Tmax (Part B)

MMAE Tmax was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · Days
PK Parameter: MMAE Tmax (Part B)
DaysPart B Expansion
Cycle 1, Dose 12.061 ± 26.838
Cycle 1, Dose 32.101 ± 28.820
SecondaryPK Parameter: MMAE AUC (Part B)

MMAE AUC was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · ng/mL*day
PK Parameter: MMAE AUC (Part B)
ng/mL*dayPart B Expansion
Cycle 1, Dose 1 - AUC Last-MMAE8.709 ± 63.747
Cycle 1, Dose 3 - AUC Last-MMAE16.578 ± 52.121
SecondaryPK Parameter: MMAE Trough Concentration (Ctrough) (Part B)

MMAE Ctrough was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · ng/mL
PK Parameter: MMAE Trough Concentration (Ctrough) (Part B)
ng/mLPart B Expansion
PK Parameter: MMAE Trough Concentration (Ctrough) (Part B)0.230 ± 82.638
SecondaryPK Parameter: Total Antibody (TAb) Cmax (Part B)

TAb Cmax was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · ng/mL
PK Parameter: Total Antibody (TAb) Cmax (Part B)
ng/mLPart B Expansion
Cycle 1, Dose 118.418 ± 28.631
Cycle 1, Dose 319.955 ± 28.405
SecondaryPK Parameter: TAb Tmax (Part B)

TAb Tmax was derived from the PK blood samples collected.

Time frame:
Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle.
Reported as:
Geometric mean · Days
PK Parameter: TAb Tmax (Part B)
DaysPart B Expansion
Cycle 1, Dose 10.041 ± 67.072
Cycle 1, Dose 30.043 ± 67.795
SecondaryPK Parameter: TAb Area Under Concentration-Time Curve (AUC) (Part B)

TAb AUC was derived from the PK blood samples collected.

Time frame:
Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose).
Reported as:
Geometric mean · µg/mL*day
PK Parameter: TAb Area Under Concentration-Time Curve (AUC) (Part B)
µg/mL*dayPart B Expansion
Cycle 1, Dose 1 - AUC 7 Days-TAb35.535 ± 24.950
Cycle 1, Dose 3 - AUC 7 Days-TAb39.371 ± 29.218
Cycle 1, Dose 3 - AUC 14 Days-TAb42.240 ± 29.206

Adverse events

Collected over Non-serious AEs were followed up to 10.5 months. Serious AEs and All-Cause Mortality were followed up to 31.6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-In 0.9 mg/kg 3Q4W6/8 (75%)2/7 (28.6%)7/7 (100%)
Safety Run-In 1.2 mg/kg 3Q4W5/8 (62.5%)4/8 (50%)8/8 (100%)
Part B Expansion53/82 (64.6%)28/79 (35.4%)77/79 (97.5%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventSafety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B Expansion
ConstipationGastrointestinal disorders0/73/81/79
AscitesGastrointestinal disorders1/70/81/79
FatigueGeneral disorders1/71/80/79
Performance status decreasedGeneral disorders1/70/80/79
CellulitisInfections and infestations1/70/80/79
Decreased appetiteMetabolism and nutrition disorders1/70/80/79
Pleural effusionRespiratory, thoracic and mediastinal disorders1/70/84/79
Abdominal painGastrointestinal disorders0/71/82/79
VomitingGastrointestinal disorders0/71/82/79
Confusional statePsychiatric disorders0/71/80/79
Most frequent other events
Showing 10 of 96
Most frequent other events
EventSafety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B Expansion
AnaemiaBlood and lymphatic system disorders4/70/823/79
DiarrhoeaGastrointestinal disorders4/72/818/79
EpistaxisRespiratory, thoracic and mediastinal disorders4/73/836/79
FatigueGeneral disorders2/74/825/79
Peripheral sensory neuropathyNervous system disorders3/72/818/79
NauseaGastrointestinal disorders2/72/830/79
Abdominal painGastrointestinal disorders0/73/822/79
ConstipationGastrointestinal disorders2/73/817/79
Nasal congestionRespiratory, thoracic and mediastinal disorders1/73/89/79
ConjunctivitisInfections and infestations2/71/825/79

Baseline characteristics

The Safety Analysis Set includes all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(Years)Safety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B ExpansionTotal
Median69.0 (50.0 to 87.0)67.5 (51.0 to 74.0)60.0 (38.0 to 81.0)62.0 (38.0 to 87.0)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Safety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B ExpansionTotal
Female787994
Intersex0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B ExpansionTotal
American Indian or Alaska Native0000
Asian0134
Native Hawaiian or Other Pacific Islander0000
Black or African American0167
White666981
More than one race0000
Unknown or Not Reported1012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Safety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B ExpansionTotal
Hispanic or Latino/a, or of Spanish Origin01910
Not of Hispanic or Latino/a, or of Spanish Origin676982
Unknown1012
Eastern Cooperative Oncology Group (ECOG) Performance Score
Eastern Cooperative Oncology Group (ECOG) Performance Score(Participants)Safety Run-In 0.9 mg/kg 3Q4WSafety Run-In 1.2 mg/kg 3Q4WPart B ExpansionTotal
Grade 0454857
Grade 1333137
08

Study locations

37 sites
  • Stanford Cancer Center South Bay
    San Jose, California 95124, United States
  • Poudre Valley Health System (PVHS)
    Fort Collins, Colorado 80524, United States
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
  • Miami Cancer Institute- Plantation (MCIP)
    Miami, Florida 33176, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • University of Missouri Healthcare / Ellis Fischel Cancer Center
    Columbia, Missouri 65212, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Mount Sinai Chelsea
    New York, New York 10011, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Fairview Hospital
    Cleveland, Ohio 44111, United States
  • Cleveland Clinic, The
    Cleveland, Ohio 44195, United States
  • Ohio State University Clinical Trials Management Office
    Columbus, Ohio 43210, United States
  • Cleveland Clinic Hillcrest Hospital
    Mayfield Heights, Ohio 44124, United States
  • Texas Oncology - Fort Worth
    Dallas, Texas 75246, United States
  • Renovatio Clinical
    The Woodlands, Texas 77380, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Algemeen Ziekenhuis Maria Middelares
    Ghent, Other 9000, Belgium
  • Universitair Ziekenhuis Leuven
    Lueven, Other 3000, Belgium
  • Aalborg Universite Hospital
    Aalborg, Other 9100, Denmark
  • Mater Private
    Dublin, Other D07 WKW8, Ireland
  • Cork University Hospital
    Wilton, Other T12 E8YV, Ireland
  • Ospedale Ramazzini di Carpi
    Carpi, Other 41012, Italy
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori- IRST S.r.l
    Meldola, Other 47014, Italy
  • Istituto Europeo di Oncologia
    Milano, Other 20141, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
    Napoli, Other 80131, Italy
  • Fondazione Policlinico Universitario Agostino
    Rome, Other 00168, Italy
  • Hospital Universitario Vall d'Hebron
    Barcelona, Other 08035, Spain
  • L'Institut Catala d'Oncologia
    L'Hospitalet de Llobregat, Other 08907, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Other 28034, Spain
  • HM Centro Integral Oncologico Clara Campal
    Madrid, Other 28050, Spain
  • Clinica Universidad de Navarra
    Pamplona, Other 31008, Spain
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcón, Other 28223, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Feb 2022, 34 months.

Results were first posted in May 2023, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 34 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2018
First posted
Sep 4, 2018
StartActual
Mar 20, 2019
Primary completionActual
Feb 8, 2022
CompletionActual
Feb 8, 2022
Results first posted
May 6, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03657043
Lead sponsor
Seagen Inc.
Collaborators
Genmab
Responsible party
Sponsor
First posted
Sep 4, 2018
Start date
Mar 20, 2019
Primary completion
Feb 8, 2022
Completion
Feb 8, 2022
Results posted
May 6, 2023
Last update
May 6, 2023

Study contacts

Kristi Schmidt, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion